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Bevacizumab is one of the VEGF-binding proteins that are established in clinical practice to treat various
ocular diseases. In view of therapeutic long-term application, potential accumulation of the antibody in
retinal cells gave reason for safety concerns. Internalization of considerable amounts of bevacizumab by
retinal endothelial (REC) and pigment epithelial cells has been observed which may affect their
important functions. Therefore we investigated the transport and intracellular localization of bev-
acizumab in immortalized bovine REC (iBREC) in detail, considering possible roles of vesicles and re-
ceptors mediating uptake and intracellular transport.
By performing transcytosis assays with iBREC monolayers cultivated on porous membrane inserts, we
demonstrated that bevacizumab was transported efﬁciently through a tight monolayer from the lower to
the upper chamber or vice versa. When added to the lower chamber in excess, the internalized antibody
was transported through the cells, but it was also recycled to be set free at the same side of the cell into a
bevacizumab-free environment. The rates of both processes strongly depended on the concentration of
fetal bovine serum (FBS) in the environment. This observation is important because in vivo REC might be
exposed to varying amounts of serum, e.g. in patients with macular edema. FBS also affected the
intracellular localization of bevacizumab as shown by analyses of subcellular fractions and direct
immunoﬂuorescence staining. When iBREC were cultivated in low-serum medium, most of the antibody
was found in the fraction of cytoskeleton proteins and spots of high intensity of bevacizumab-speciﬁc
staining close to the nuclei were observed. Cultivation in medium with FBS resulted in internalized
bevacizumab predominately found in the membrane/organelle fraction in addition to its weaker asso-
ciation with proteins from the cytoskeleton and uniform staining of the cell. Bevacizumab-speciﬁc
staining close to the cytoskeleton proteins a-tubulin or vimentin was also observed. Accumulation and
association of the antibody with the cytoskeleton induced by serum reduction could be reversed by
subsequent FBS addition. In uptake and transport of bevacizumab vesicles and binding to a receptor
seems to be involved: Internalization was strongly temperature-dependent which ruled out paracellular
passage and a fraction of the internalized bevacizumab was associated with early endosomes. Protein A
inhibited transcytosis and affected intracellular localization suggesting a key role of the neonatal Fc
receptor (FcRn). Interestingly, FcRn expression was decreased when iBREC were cultivated without FBS.
Our results suggest this pathway of bevacizumab uptake and transition through iBREC: Independent of
serum, bevacizumab is taken up through a nonspeciﬁc mechanism. The subsequent sorting into transport
vesicles depends on the presence of serum as regulator of FcRn expression. Without sufﬁcient amounts
of the receptor being expressed, a likely obstructed exocytosis results in intracellular accumulation and
an increased association with cytoskeleton proteins. Interaction of substantial amounts of bevacizumab
with the cytoskeleton may be the reason for under these conditions suppressed migration of iBREC. If
long-term therapies by intravitreal injection lead to accumulation of bevacizumab in REC in vivo and
potentially harmful consequences, will have to be revealed by future investigations.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).logy, University of Ulm, Prittwitzstrasse 43, 89075 Ulm, Germany.
(H.L. Deissler).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nomenclature
BSA bovine serum albumin
EC endothelial cells
ECGM endothelial cell growth medium
EEA1 early endosome antigen 1
FcRn neonatal Fc receptor
FBS fetal bovine serum
hEGF human epidermal growth factor
HMEC human dermal microvascular endothelial cells
(i)BREC (immortalized) bovine retinal endothelial cells
MAb monoclonal antibody
MDCK MadineDarby canine kidney epithelial cells
PBSd phosphate buffered saline without Ca2þ and
without Mg2þ ions
REC retinal endothelial cells
RPEC retinal pigment epithelial cells
SFM serum-free medium
SHM SFM with 5% FBS
SRM SFM with 1% FBS
TJ tight junction
VEGF(-A)vascular endothelial growth factor (A)
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The development and clinical manifestation of macular edema
in patients with diabetic retinopathy, retinal vein occlusion and
age-related macular degeneration are associated with de-regulated
expression of various cytokines. Of these, up-regulation of vascular
endothelial growth factor (VEGF-A) is considered very important,
and several proteins that speciﬁcally bind to VEGF-A have become
valuable therapeutic agents: Fab-fragment ranibizumab and the
recombinant aﬂibercept which additionally targets other members
of VEGF-family, have been approved for the treatment of the
aforementioned conditions whereas the humanized antibody
bevacizumab is currently used off-label (Arevalo et al., 2011; Do
et al., 2012; Ferrara et al., 2006; Holash et al., 2002; Lang et al.,
2013; Mitchell et al., 2011; Presta et al., 1997). Their VEGF-
blocking activities have been conﬁrmed in experiments with
retinal endothelial cells (REC) of bovine and human origin, indi-
cating that bevacizumab is slightly less efﬁcient than ranibizumab
or aﬂibercept (Deissler et al., 2008, 2011, 2012, 2013, 2014; Stewart
et al., 2011). Recent investigations, however, indicate that despite
similar anti-VEGF activities, the distinct structural features of these
proteins result in different indirect effects of potential relevance to
therapeutic applications: In contrast to ranibizumab, bevacizumab
and aﬂibercept can be internalized by immortalized bovine REC
(iBREC); and both nonspeciﬁcally inhibit iBREC migration when
present at amounts which could be achieved in vivo by intravitreal
injection (Deissler et al., 2012, 2014). Bevacizumab and aﬂibercept
are also internalized by retinal pigment epithelial cells (RPEC), a
process which seems to impair phagocytosis (Klettner et al., 2009,
2010, 2014). In wound healing assays, only aﬂibercept of the three
VEGF inhibitors inhibited closure of the monolayers formed by
iBREC or RPEC (Deissler et al., 2014; Klettner et al., 2014).
The mechanism of bevacizumab's internalization by iBREC is
not clear and potential roles of vesicles and receptors mediating
uptake and intracellular transport have to be considered. An
obvious candidate for a receptor involved in shuttling IgGs or
structurally related proteins is the neonatal Fc receptor (FcRn)
which indeed is expressed in the retinal endothelium (Junghans
and Anderson, 1996; Kim et al., 2008; Powner et al., 2014). FcRn
is a key factor in transcytosis and recycling of IgG and albumin,which are processes used by endothelial cells (EC) of various or-
igins to maintain homeostasis of these serum proteins. In EC, FcRn
is localized in acidic vesicles where it binds to IgG proteins that
have been internalized by pinocytosis (Goebl et al., 2008; Ober
et al., 2004). Receptor-bound IgG is then recycled to the cell sur-
face thereby avoiding degradation in lysosomes. FcRn is a heter-
odimer consisting of two non-covalently linked subunits: b2-
microglobulin and a larger polypeptide related to major histo-
compatibility complex class I proteins. IgGs and albumin but not
IgA or IgM, are bound independently at different sites by the
larger subunit of the FcRn at low pH and released at physiological
pH (Junghans and Anderson, 1996; reviewed in: Sand et al., 2015).
It is interesting and of relevance for our investigation based on
iBREC that FcRn is a highly conserved receptor, reﬂected by very
similar human and bovine homologues in which the sequences of
the IgG binding regions of FcRn are even identical (Kacskovics
et al., 2000). Accordingly, several studies have shown that hu-
man IgG is indeed efﬁciently bound and transported through
transcytosis by bovine FcRn (Cui et al., 2014; Kacskovics et al.,
2006; Ober et al., 2001). In addition to FcRn-mediated pro-
cesses, other pathways might contribute to IgG trafﬁcking: Com-
plexes consisting of IgG and the extracellular matrix proteins
ﬁbronectin and/or heparin can be internalized by EC through their
association with integrins (Fujii et al., 2003).
Based on the aforementioned results, revealing a potential
permeability of EC for IgG and IgG-related proteins, and on the
growing concern that high amounts of IgG in the vitreous might be
harmful due to their accumulation in different ocular cell types, we
investigated the transport and intracellular localization of bev-
acizumab in iBREC in detail. The conﬁrmed involvement of the FcRn
in such processes suggested to focus on its potential contribution.
In addition, the effect of fetal bovine serum (FBS) was studied
because REC are exposed to different concentrations of serum
during the pathogenesis of macular edema.
2. Materials and methods
2.1. Antibodies and reagents
The humanized anti-VEGF antibody bevacizumab (Avastin;
25 mg/ml in 50 mM sodium phosphate, 6% a,a-trehalose dihydrate,
0.04% polysorbate 20, pH 6.2; Presta et al.,1997) was purchased from
Roche Pharma (Grenzach-Wyhlen, Germany) and aliquots of the
antibody solutionwere stored for less than fourweeks in inert plastic
vials. Alternatively, the bevacizumab solutionwas repackaged at the
pharmacy of the University Hospital Ulm and provided in syringes
whichwere storedat4 C forno longer than fourweeks.Bevacizumab
obtained from these sources gave rise to the same results.
Rabbit polyclonal antibodies (NBP1-89127) binding to the human
neonatal Fc receptor and a mouse monoclonal antibody (MAb) spe-
ciﬁc for bovine serum albumin (BSA; Clone 25G7, NBP1-05155) were
originally from Novus Biologicals (Acris Antibodies, Herford, Ger-
many or bio-techne, Wiesbaden, Germany). Detection antibodies
(F(ab')2 labeled with Alexa Fluor 594 or Alexa Fluor 488) were from
Thermo Scientiﬁc (Karlsruhe, Germany). Horseradish peroxidase-
conjugated detection antibodies directed against rabbit or mouse
IgG were bought from BioRad (Munich, Germany), those used to
speciﬁcally detect human IgG from Thermo Scientiﬁc. Rabbit poly-
clonal antibodies recognizing von Willebrand Factor (vWF) were
purchased fromDakoGmbH (Hamburg, Germany) and amouseMAb
(CC25) against CD63 fromAcrisAntibodies.MouseMAbsdetectinga-
tubulin (clone DM1A) or vimentin (clone RV202), and rabbit poly-
clonal antibodies (ab137403) directed against early endosome anti-
gen 1 (EEA1), an early endosome marker protein, were all obtained
from Abcam (Cambridge, UK). Recombinant human control peptide
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Germany). The recombinant, E. coli-expressed IgG-binding proteins
Protein A (from Staphylococcus aureus), Protein G (from group G
Staphylococci), and Protein L (from Peptostreptococcus magnus) were
purchased from Thermo Scientiﬁc. BSA (fraction V, pH 7)was bought
from Serva GmbH (Heidelberg, Germany).
2.2. Cultivation of iBREC
Telomerase-immortalized microvascular endothelial cells from
bovine retina iBREC were established and characterized in our labo-
ratory (Deissler et al., 2005). The amount of human telomerase
reverse transcriptase measured in iBREC was similar to that of the
bovine enzymeexpressedby shortlycultivatedprimaryBRECanddid
not result in signiﬁcant changes of the phenotype: More than 99% of
the iBREC in a typical culture express the ECmarkers vonWillebrand
factor, vascular endothelial cadherin, various tight junction (TJ)-
proteins as well as VEGF receptors-1, -2 and neuropilin-1, which was
conﬁrmedevery fewweeksduringprolongedcultivation. Inaddition,
maintenanceof their cobble-stonemorphologywasmonitored every
other day by microscopy (Deissler et al., 2005, 2008, 2011). iBREC
were cultivated in Endothelial Cell Growth Medium MV (ECGM;
Promocell, Heidelberg, Germany) containing 0.4% Endothelial Cell
Growth Supplement/H (with 90 mg/ml Heparin), 10 ng/ml human
epidermal growth factor (hEGF), 2.8 mM hydrocortisone and 5% FBS
on ﬁbronectin-coated (1 mg/cm2; Corning, Amsterdam, The
Netherlands) surfaces as previously described (Deissler et al., 2005,
2011). Cells were used in the experiments at passages 20 to 40
counting from the stage of primary culture, for which stable
expression of EC marker proteins had been conﬁrmed.
2.3. General considerations
All experiments e repeated at least three times - were per-
formed with conﬂuent monolayers of iBREC which were estab-
lished 3e4 d after passaging and control cells were identically
processed in medium only lacking the effector(s) under investiga-
tion. To avoid a pH or temperature shock, fresh culture mediumwas
always sufﬁciently pre-equilibrated. Bevacizumab was used at a
ﬁnal concentration of physiologically achievable 250 mg/ml (~2 mM)
unless stated otherwise.
2.4. Treatment of iBREC with effectors
To study the effect of FBS on internalization of bevacizumab into
iBREC, cells were kept in serum-free medium (SFM; same as ECGM
without hEGF, FBS and with 103 nM hydrocortisone) or this me-
dium supplemented with 5% FBS (resulting in SHM) or 1% FBS
(SRM) for 24 h. The culture medium was then partly replaced by
medium containing bevacizumab, and iBREC were incubated for
additional 2, 4 or 24 h before cells were harvested for subsequent
analyses. In similar experiments, iBREC were exposed for 1 d to
bevacizumab in SRM (1% FBS) followed by incubation for another
day after addition of FBS to a ﬁnal concentration of 5%.
In experiments to investigate effects of BSA on the uptake of
bevacizumab by iBREC, cells pre-incubated for 24 h in SFM (0% FBS)
were exposed to bevacizumab in SFM plus 0.25% BSA for 4 h before
the cells were analyzed. Similar experiments were performed with
2 mg/ml ﬁbronectin instead of BSA. To explore potential competitive
effects of proteins binding to IgG domains on the internalization of
bevacizumab, iBREC were cultured in SHM with bevacizumab and
Protein A (with ﬁve Fc binding sites, 2 or 10 mM ﬁnal concentrations),
Protein G (two Fc binding sites, 5 or 25 mM) or Protein L (binding four
IgG at the k light chain, 2.5 or 12.5 mM) for 4 h prior to analyses.
Temperature effects were investigated by cultivation of iBRECfor 24 h at 37 C before the medium was completely replaced by
pre-equilibrated medium containing bevacizumab. Then cells were
incubated at 4 C or 37 C for additional 4 h.
2.5. Preparation of cell extracts and western blot analyses
Whole cell extracts were prepared from fresh or frozen cell
pellets as described (Deissler et al., 2012). Subcellular fractions, i.e.
proteins localized in the cytoplasm, in membranes/organelles, and
components of the cytoskeleton, were also prepared from cell
pellets with the ProteoExtract Subcellular Proteome Extraction Kit
(MerckMillipore, Schwalbach, Germany) and protein concentration
in the samples were determined using the Pierce Thermo Scientiﬁc
BCA Protein Assay Kit according to the manufacturer's instructions
(Deissler et al., 2012). All Western blot analyses were performed
under reducing conditions as described; 10 mg protein was loaded
per lane (Deissler et al., 2014).
2.6. Transcytosis assays
Transcytosis assays (see drawing in Fig. 1A) were performed to
assess transport of bevacizumab through an iBREC monolayer
(Antoheetal., 2001):Cellsweregrownonpolyethylene terephthalate
membrane inserts (4.7 cm2, pore size 0.4 mm; Costar, Corning) which
had been coated overnight with 5 mg/cm2 ﬁbronectin at 4 C.
Conﬂuent iBREC monolayers formed after 4 d of cultivation were
incubatedwith SHM, SRM or SFM for 24 h before bevacizumab (with
or without effectors) was added either to the upper (apical; 1.5 ml
totalvolume)or lower (basal; 3ml total volume) chamber. Samplesof
75 ml were taken from the medium in the opposite chamber imme-
diately after addition of bevacizumab and at various time points. The
amounts of bevacizumab in these were determined byWestern blot
analyses. Similar experiments were carried out in SHMwith 250 mg/
ml (~2 mM) bevacizumab in the presence of 10 mM Protein A or
12.5 mM Protein L in the lower chamber. Samples (75 ml) were taken
from the upper chamber 0e24 h after addition of the IgG-binding
proteins and analyzed by Western blot.
Effect of BSA on bevacizumab transport in the absence of FBS was
evaluated by adding 0.25% BSA together with 250 mg/ml bev-
acizumab to the bottom chamber and analyzing samples taken from
the top chamber 0e6 h after addition of both proteins.
To determinewhether internalized bevacizumab is recycled (see
drawing in Fig. 1D; Antohe et al., 2001) or transported to the
opposite cell surface, conﬂuent iBREC were incubated with bev-
acizumab in SHM in the bottom chamber for 24 h. Then the culture
medium in both chambers was completely removed, cells thor-
oughly washed twice with fresh culture medium and covered with
1 ml medium without bevacizumab. Traces of extracellular bev-
acizumab were removed from the outsides of the inserts by sub-
merging them in bevacizumab-free culture medium in a fresh
multi-well plate. This washing step was repeated before the
insert was placed in 2 ml SHM in a fresh plate. To determine the
amounts of released bevacizumab byWestern blot, samples of 75 ml
were taken from both chambers immediately and after re-
cultivation for 24 h. Considering potential effects of FBS, similar
experiments were carried out with cells cultivated in SRM.
During these experiments, cells were carefully monitored by
microscopy to conﬁrm the integrity of the established conﬂuent
monolayers. Experiments were completed by ﬁxing the cells, still
attached to the inserts, with methanol in 5 min at 20 C. Nuclei
were visualized with DAPI-Vectashield and/or presence of TJ-
protein claudin-5 was analyzed by immunoﬂuorescence staining
(Deissler et al., 2012). Single experiments in which ﬂuid exchange
due to hydrostatic pressure between the monolayer-separated
compartments had been observed, were not evaluated. To avoid
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were always handled on a warm plate at 37 C.
Membrane inserts devoid of iBREC were similarly processed to
provide controls without a cell barrier.
2.7. Immunoﬂuorescence staining
Conﬂuent monolayers of iBREC on ﬁbronectin-coated two-
chamber slides (x-well PCA tissue culture chambers; Sarstedt,
Nuermbrecht, Germany) were exposed to bevacizumab as described
above. After removal of the chamber, slides were washed in phos-
phate buffered saline (PBSd). Fixed cells (15 min in methanol
at20 C)were treatedwith blocking solution (10% FBS/PBSd or 10%
ImmunoBlock/PBSd; Roth, Karlsruhe, Germany) for 90 min and
internalized bevacizumab was detected by incubation for 30 min
with polyclonal antibodies (1:10,000) against human IgG, coupled to
Alexa Fluor 594. For double-immunoﬂuorescence staining, slides
were subsequently incubated with antibodies (diluted in 1% FBS/
PBSd) against CD63 (1:80), EEA1 (13 mg/ml, diluted in 1% Immuno-
Block/PBSd), a-tubulin (1 mg/ml) or vimentin (1 mg/ml) for 90 min.
Alexa Fluor 488-conjugated (F(ab')2) fragments were then used to
detect the bound primary rabbit or mouse antibodies. Eventually,
the chamber slides were washed and the cells embedded in
ProLong-DAPI (Thermo Scientiﬁc) for examination by ﬂuorescenceFig. 1. Transport of bevacizumab through iBREC and its recycling are serum-dependent proces
(A) Schematic representation of the transcytosis assay: Conﬂuent iBREC grown on a porous m
the lower chamber and samples were taken from the upper chamber. (B) Bevacizumabwas ad
the iBREC monolayer (þiBREC) or its diffusion through cell-free membrane inserts (-iBREC) w
transport of bevacizumab was considerably slower than diffusion through uncovered pores. (
0e5% FBS were evaluated. Transport of bevacizumab was strongly promoted by FBS. (D), (E
exposed to 5% FBS. (D) Schematic representation of the assay used to assess recycling: To the l
before the medium in both compartments was replaced by fresh bevacizumab-free medium
chambers 24 h later. (E) Bevacizumab placed in the lower chamber could be detected 24 h later
in the lower chamber after subsequent cultivation for 24 h in medium with 5% FBS, but notmicroscopy (Leica DM4000B, Wetzlar, Germany).
3. Results
This studywasbasedontheobservation that iBREC internalize and
accumulate bevacizumab when exposed to physiological achievable
concentrationsof250mg/ml (~2mM).Uptake canbespottedasearlyas
1 h after addition and the internalized bevacizumab remains detect-
able - with polyclonal antibodies directed against human IgG - inside
the cells for several days (Deissler et al., 2012).
3.1. FBS accelerates transcytosis of bevacizumab through an iBREC
monolayer
We evaluated whether bevacizumab was transported by iBREC
from the basal side to the opposite cell surface by performing
transcytosis assays with iBREC monolayers cultivated on
ﬁbronectin-coated porous membrane inserts. Bevacizumab (with/
without effectors) was added to the lower chamber (contact with
the basal cell membrane) and samples were taken from the upper
chamber (above the apical cell membrane) at various time points
between 2 h and 2 d (Fig. 1A, B) to determine the amounts of
bevacizumab released into the medium. Free diffusion of bev-
acizumab through the pores of the insert was much faster than itsses. (A)e(C) Transport of bevacizumab through an iBREC monolayer is serum-dependent.
embrane were exposed at their basal side to bevacizumab which was therefore placed in
ded to the lower chamber at a ﬁnal concentration of 250 mg/ml and its transport through
as monitored by Western blot analyses of samples from the top chamber. Cell-mediated
C) Bevacizumab was added to the bottom chamber and its transendothelial transport at
) Bevacizumab is recycled and released from the basal surface of an iBREC monolayer
ower of the two chambers separated by conﬂuent iBREC, bevacizumab was added for 1 d
. Bevacizumab was determined by Western blot analyses of samples taken from both
in the opposite chamber. After complete removal of the IgG, tiny amounts were detected
when medium with only 1% FBS had been used.
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of diffused and transported bevacizumab in the top chamber were
comparable (Fig. 1B). A similar equilibration of the concentrations
in both compartments was observedwhen bevacizumabwas added
to the upper chamber and samples taken from the lower chamber
were analyzed (data not shown). In subsequent experiments,
however, bevacizumab was added to the lower chamber because
after intravitreal injection the basal side of the REC layer of the
vessel walls is primarily exposed to the drug.
On the grounds that the REC environmentmight contain varying
amounts of serum, e.g. during the pathogenesis of macular edema,
potential effects of FBS on bevacizumab's transport through iBREC
were studied (Fig. 1C). As expected, diffusion in the absence of cells
was not affected under these conditions. In medium devoid of FBS,
transport of bevacizumabwas slower compared to 1% FBS or 5% FBS
which resulted in fastest transition. Interestingly, increasing the
FBS concentration to 5% in the upper chamber without any FBS in
the lower chamber had the same effect on transport as 1% FBS in
both compartments.
Exposing iBREC to VEGF-A165 in medium containing 0.25% FBS
for 1 d reduces the transendothelial resistance measured as means
of permeability which is then restored to normal values within 24 h
after addition of bevacizumab (Deissler et al., 2012). Under these
conditions, transition of bevacizumab from the lower to the upper
chamber was also accelerated (not shown).
Taken together, we demonstrated that bevacizumab is trans-
ported through a tight iBREC monolayer and the rate of this pro-
cess strongly depends on the concentration of FBS in the
environment.
3.2. Recycling of bevacizumab is serum-dependent
Bevacizumab internalized by iBREC can either be transported
through the cells to the opposite region of the cell membrane
(Fig. 1D, gray arrow) or recycled to be released from the side it came
from (Fig. 1D, black arrow). A considerable fraction of the bev-
acizumab added to the basal side of an iBREC monolayer was
detected in the chamber adjacent to the apical side after 24 hwhich
is indicative of uptake and transport of bevacizumab across the cells
(Fig. 1E). After the medium in both chambers (containing 5% FBS)
had been completely replaced by bevacizumab-free medium with
5% FBS and the subsequent cultivation for additional 24 h, a small
amount of bevacizumab was found in the lower but not in the
upper chamber (Fig. 1E). This was not observed when medium
containing only 1% FBS was used.
Obviously, bevacizumab is recycled to be set free at the basal
surface of iBREC into a bevacizumab-free environment, but it is
transported through the cells of the monolayer when present in
excess. The rates of both processes are strongly affected by the
amount of serum the cells are exposed to.
3.3. FBS also affects intracellular localization of bevacizumab
We hypothesized that an increased transport of bevacizumab
due to higher FBS concentrations might be associated with a
different intracellular localization of the IgG. To test this assump-
tion, iBRECwere treatedwith bevacizumab in the presence of 0e5%
FBS. Western blot analyses of subcellular fractions prepared after 2,
4 or 24 h showed that more bevacizumabwas internalized at lower
FBS concentrations (0% or 1%) and that most of it was co-extracted
with cytoskeleton proteins (Fig. 2A). Only a minor amount was
localized in the membrane/organelle fraction. Prolonging the in-
cubation time for 24 h resulted in an even more pronounced dif-
ference in favor of association with proteins in the cytoskeleton
fraction. The amount of mainly cytoskeleton-associatedbevacizumab was lower when medium with 1% FBS was used, and
with 5% FBS, accumulation of the IgG was strongly suppressed.
Immunoﬂuorescence staining of iBREC treated with bev-
acizumab revealed different intracellular localizations of the IgG
depending on presence or absence of FBS: Strong uniform staining
of whole cells was observed after cultivation in medium with 5%
FBS whereas in the absence of FBS, bevacizumab was predomi-
nantly seen close to the nuclei (Fig. 2B). In accordance with the
analysis of subcellular fractions, a part of the internalized bev-
acizumabwas detected close to the cytoskeleton proteins a-tubulin
or vimentin which are important for cellular transport or stability
(Fig. 3). Bevacizumab-speciﬁc dots aligned along the a-tubulin ﬁ-
bers were concentrated and therefore most easily detectable at the
plus ends of the a-tubulin ﬁbers in the spike-like extensions of the
cells (Fig. 3, red arrows). Overlapping staining of bevacizumab and
a-tubulin at the origins of the microtubules close to the nucleus
was not observed; their staining rather resulted in a mosaic pattern
in these regions. A fraction of the bevacizumab-speciﬁc signals
seemed to overlap with the vimentin staining close to the nucleus
(Fig. 3, white arrow) in addition to the bevacizumab dots near
vimentin ﬁbers that extend to the cytoplasm (Fig. 3). The staining
patterns and intensities of both investigated cytoskeleton proteins
were not affected by cultivation of the cells in the presence of
bevacizumab.
3.4. Accumulation of bevacizumab induced by serum depletion is
reversible
To investigate whether the FBS-dependent accumulation of
bevacizumab turning up in the subcellular fraction of cytoskeleton
proteins is reversible, iBREC were treated for 1 d with the antibody
in the presence of 1% FBS before more serumwas added to achieve
a ﬁnal concentration of 5% at which cells were kept for another day
(Fig. 4A). During this period of cultivation with more FBS, the
amount of intracellular bevacizumab presumably associated with
the cytoskeleton decreased substantially.
Albumin, at a concentration ~50 g/l the major component of
serum, was considered an obvious candidate for the factor pre-
venting bevacizumab's intracellular enrichment and attachment
to components of the cytoskeleton. Therefore iBREC were incu-
bated with serum-free medium for 24 h before bevacizumab
together with 0.25% BSA was added for additional 4 h after which
only a very small amount of bevacizumab could be detected in the
cytoskeleton fraction (Fig. 4B). In accordance with these ﬁndings,
delayed transport of bevacizumab in the absence of FBS was
accelerated by addition of 0.25% BSA (data not shown). This sup-
ports the assumption that presence of albumin determines the
intracellular localization of bevacizumabwhich can then be sorted
properly for further transport or recycling only when BSA (or FBS)
are present.
It has been reported that the extracellular matrix protein
ﬁbronectin might be involved in the uptake of IgG by macro-
vascular EC (Fuji et al., 2003). However, incubation of iBREC with
bevacizumab in the presence of physiologically relevant 2 mg/ml
ﬁbronectin resulted in a slightly increased amount of bevacizumab
found in the fraction of cytoskeletal proteins whereas the amount
associated with membrane/organelle proteins was unchanged
(Fig. 4).
3.5. Uptake of bevacizumab is temperature-dependent
The uptake of bevacizumab by iBREC followed by its intracel-
lular transport is potentially due to non-speciﬁc endocytosis and
vesicle trafﬁcking. At lower temperature, these processes are
considerably slowed down, in contrast to less affected paracellular
Fig. 2. Localization of bevacizumab internalized by iBREC is serum-dependent. (A) iBREC were pre-incubated for 24 h with culture medium containing various concentrations of FBS
and were then treated with 250 mg/ml bevacizumab in the same medium for additional 2, 4 or 24 h before subcellular fractions were prepared. Equal amounts of these (~10 mg
protein) were analyzed by Western blot to determine bevacizumab. When cells had been cultivated in medium with 5% FBS, bevacizumab was detected in both the membrane/
organelle and cytoskeleton fractions. Lower concentrations of FBS or cultivation without serum resulted in very strong bevacizumab-speciﬁc bands assigned to the fraction con-
sisting of cytoskeleton proteins. (B) iBREC were treated as described in (A) and bevacizumab was visualized by immunoﬂuorescence staining. Cells cultivated with 5% FBS showed a
nearly homogenous intracellular staining, whereas without FBS, bevacizumab was mainly observed in a region close to the nucleus.
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bevacizumab found in membrane/organelles or cytoskeleton frac-
tions were both lower when the cells were temporarily cultivated
at 4 C (Fig. 5A) supported the concept of active processes leading to
bevacizumab uptake and transition through the cells.3.6. A fraction of bevacizumab internalized by iBREC is associated
with EEA1-positive vesicles
Because vesicles are likely involved in uptake or transport of
bevacizumab, iBREC treated with bevacizumab for 4 h (with or
without FBS) were stained with antibodies recognizing early
endosomes (marker EEA1) or late secretory endosomes (CD63) in
combination with visualization of bevacizumab (Jerdeva et al.,
2010; Kobayashi et al., 2000; Ward et al., 2005). The patterns of
staining with these antibodies were not affected by presence of
bevacizumab in the culture medium. Co-localization of bev-
acizumab with CD63 was not observed. CD63-positive vesicles
were evenly distributed in the presence of FBS, however, in its
absence the pattern resulting from staining of CD63 was patchy
(Fig. 5B). A uniform EEA1-speciﬁc staining of the cells was observed
after cultivation in medium with 5% FBS which was weaker and
more pronounced close to the nucleus without FBS. A fraction of the
bevacizumab inside iBREC was clearly co-localized with EEA1,
particularly in areas close to the nucleus (Fig. 5B).3.7. Protein A but not Protein L delays transcytosis of bevacizumab
and affects its intracellular localization
Binding of bevacizumab to the neonatal Fc-receptor FcRn might
be involved in its uptake or transport at some stage. This assump-
tion is based on the following observations: Intracellular transport
of IgG involves its binding to the FcRn in human microvascularendothelial cells, and in MadineDarby canine kidney epithelial
cells (MDCK) FcRn and taken up IgG are co-localized in EEA1-
positive early endosomes (Goebl et al., 2008; Jerdeva et al., 2010).
To test if FcRn plays a role in absorption and processing of bev-
acizumab, iBREC transcytosis assays were carried out in the pres-
ence of Protein A in medium containing 5% FBS. Protein A binds to
the same IgG region as FcRn (Raghavan et al., 1994). Its effect was
compared with that of Protein L that binds to the light chain of the
k-type and, therefore, does not compete with FcRn for binding the
IgG (Nilson et al., 1993). Prior to the experiments, we conﬁrmed
that both Protein A (with ﬁve IgG-binding sites) and Protein L (four
sites) strongly bind to bevacizumab. In the transcytosis assays,
performed in the presence of a ~ 5fold molar excess of either IgG-
binding protein for 24 h, a markedly delayed transport of bev-
acizumab was observed only in the presence of Protein A but not
with Protein L (Fig. 6A).
To investigate whether binding of bevacizumab to FcRn inhibits
its uptake or affects its intracellular localization, iBRECwere treated
for 4 h with 2 mM bevacizumab and 2 or 10 mM Protein A in the
presence of 5% FBS. Under these conditions, bevacizumab that had
been taken up by the cells was no longer associated with proteins
from membranes and organelles but was found only in the cyto-
skeleton fraction (Fig. 6B). Results were similar when Protein Awas
substituted with Protein G which also competes with the FcRn for
binding to IgG. In contrast, the amount of bevacizumab associated
with themembrane/organelle fractionwas not affected by Protein L
(Fig. 6B).3.8. FBS affects expression of FcRn by iBREC
Based on our results suggesting that binding to the FcRn is
important for transport and processing of bevacizumab in iBREC,
we studied potential effects of FBS in the culture medium on
Fig. 3. Intracellular bevacizumab co-localizes with cytoskeleton proteins iBREC were
treated with 250 mg/ml bevacizumab for 4 h before internalized bevacizumab was
immunostained (red). Vimentin and a-tubulin were stained green with speciﬁc anti-
bodies and appropriate detection antibodies coupled to Alexa Fluor 488. Bevacizumab
speciﬁc dots were aligned along vimentin or a-tubulin (red arrows). In addition, a vast
amount of bevacizumab was seen close to the nucleus, and at least a part of these
signals were overlapping with the vimentin staining (white arrow).
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speciﬁcity of the signals (strong band at 40 kDa, faint band at
36 kDa) generated with the anti-FcRn antibody was conﬁrmed by
successful competition with a peptide similar to that used for im-
munization (not shown). The faint band observed at 36 kDa is most
likely due to a splice variant lacking exon 6 (Kacskovics et al., 2000).
In accordance with the reported localization of the receptor, FcRn
was found in the membrane/organelle fraction but not together
with proteins assigned to the cytosol or cytoskeleton (Fig. 7A).
Western blot analyses of the membrane/organelle fraction pre-
pared 2, 4 or 24 h after addition of bevacizumab to medium with
0e5% FBS, are shown in Fig. 7B. Remarkably, the amount of FcRn in
this subcellular fractionwasmuch lower when the concentration of
FBS in the medium had been reduced (Fig. 7B, C). The measured
expression of FcRn in iBREC cultivated with 1% FBS was very low
but higher amounts could be reestablished by subsequent addition
of FBS (Fig. 7C). Weak expression of the FcRn under low serum
conditions, determined by analyses of whole cellular extracts or
membrane/organelle fractions, was not obviously affected by bev-
acizumab but markedly increased after addition of VEGF-A165
(100 ng/ml, 1 d).4. Discussion
Various ocular diseases are treated by intravitreal injection of
one of the VEGF-binding proteins bevacizumab, aﬂibercept or
ranibizumab (Arevalo et al., 2011; Do et al., 2012; Mitchell et al.,
2011). After their VEGF-depleting capacities having beenconﬁrmed in numerous studies, these drugs are now well estab-
lished in clinical practice. However, in view of therapeutic long-
term application of these proteins, their potential accumulation
in ocular structures and cells gave reason for some safety concerns
(Julien et al., 2014; Lang et al., 2014; Schraermeyer and Julien, 2012).
Internalization of considerable amounts of aﬂibercept and bev-
acizumab by retinal cells has been observed and found to be of
relevance to important functions (Aboul Naga et al., 2015; Deissler
et al., 2012, 2014, Klettner et al., 2009, 2010, 2014). As demonstrated
in a rodent model, the retinal capillaries are involved in the clear-
ance of therapeutic IgG in the eye (Kim et al., 2009). To understand
intracellular transport of bevacizumab and the factors affecting the
relative amounts that are subsequently released from both sides of
the REC monolayer is therefore not only of general interest but
relevant to the pharmacological assessment of the IgG and related
proteins injected into the vitreous.
In the absence of permeability-inducing factors, the retinal
endothelium is a homogeneous and tight layer with only a very
small space between individual cells which is deﬁned by stably
established tight junctions (Hofman et al., 2000). An IgG
(Ø ~ 100 nm) appears to be too large to pass through such a
small intercellular gap (Ø ~ 45 nm) (Pappenheimer et al., 1951).
Considering these facts, an active transport of bevacizumab
across the ((i)B)REC monolayer, potentially involving vesicles
and speciﬁc receptors, is very likely. The IgG-binding FcRn is an
obvious candidate receptor that may play a role in this process
and it was found to be expressed by iBREC and up-regulated
when the cells were exposed to FBS or VEGF-A165. Several
ﬁndings of this study indeed suggest that the FcRn, which is
known to be involved in transcytosis and recycling of IgG and
albumin by EC of various origins, is also important for accurate
sorting and transport of bevacizumab through iBREC. Trans-
cytosis and recycling of considerable amounts of bevacizumab
were observed only when iBREC expressed the FcRn and the
localization of the internalized antibody also depended on
presence of this receptor: Efﬁcient transcytosis was observed
when FBS, BSA or VEGF-A165 was in the medium and, as a
consequence, FcRn was expressed strongly. When on the other
hand, the expression of FcRn was decreased by cultivation of
iBREC in serum-free medium only low amounts of bevacizumab
were transported. Under these conditions associated with an
impeded transport, bevacizumab was still taken up but accu-
mulated in a way that led to its co-enrichment with cytoskeleton
proteins. The obvious correlation between presence of serum,
FcRn expression and transport or, respectively, accumulation was
conﬁrmed by experiments in which after serum-free cultivation,
subsequent addition of serum (or its main component albumin)
restored the FcRn and shifted bevacizumab back to the mem-
brane/organelle fraction. That expression of the FcRn is regu-
lated by albumin seems plausible as its physiological functions
include the transport of albumin into endothelial cells, though
albumin and IgG bind to different sites of the receptor (Junghans
and Anderson, 1996, reviewed in: Sand et al., 2015). In the
absence of extracellular albumin, iBREC obviously do not need
FcRn to meet physiological requirements. Taken together, our
results suggest that accurate sorting and transport of bev-
acizumab by iBREC strongly depends on the presence of the
serum-regulated FcRn.
Uptake and subsequent transport of bevacizumab through
iBREC were strongly delayed in the presence of an excess of Protein
A, the IgG-binding protein of S. aureus. Interestingly, the detergent-
soluble part of internalized bevacizumab which associated with
proteins of the membranes/organelles was so strongly affected by
Protein A that it was no longer detectable, in contrast to the portion
still found in the cytoskeleton fraction. It seems likely that this was
Fig. 4. Accumulation of bevacizumab in iBREC is reversible. (A)e(C) Detection of bevacizumab by western blot analysis in subcellular fractions (10 mg protein per lane) of iBREC
exposed to bevacizumab under various conditions. (A) Conﬂuent iBREC were treated with 250 mg/ml bevacizumab for 2 d in medium with 1% or 5% FBS, or in medium with 1% FBS
for 1 d before FBS was increased to 5% for another day. After incubation with 1% FBS, most of the bevacizumab was found in the fraction containing cytoskeleton proteins and this
portion strongly decreased when the FBS concentration was brought to 5%. (B) iBREC cultivated in medium without FBS for 24 h were treated with bevacizumab for additional 4 h
with or without 0.25% BSA, before subcellular fractions were prepared. The strong accumulation of bevacizumab in the cytoskeleton fraction was not observed when BSA had been
added to the medium. (C) Bevacizumab was detected in subcellular fractions of iBREC treated with bevacizumab together with ﬁbronectin for 4 h. Fibronectin did not have an effect
on the enrichment of bevacizumab in the fraction of membrane/organelle proteins but the amount of bevacizumab associated with cytoskeletal proteins was slightly increased.
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because both proteins have overlapping binding sites on the Fc
terminus of an IgG, whereas the other Fc receptors, FcgRI and
FcgRIIa, bind to different regions of the IgG (Raghavan et al., 1994;
Wines et al., 2000). Furthermore, it has been conﬁrmed that
binding of human IgG to the human FcRn in vitro can be blocked by
a 10fold molar excess of a fragment derived from Protein A
(Raghavan et al., 1994). Inhibition by Protein A in conjunction with
our ﬁnding that uptake of bevacizumab was considerably reduced
at a lower temperature, indicative of an active transport rather than
paracellular passage, strongly suggests that at least part of the
internalized bevacizumab is associated with the FcRn in vesicle-
mediated transport processes. Direct visualization of the FcRn by
immunoﬂuorescence staining was not possible because the avail-
able speciﬁc antibody directed against the heavy chain of the re-
ceptor was not suitable for this technique (Powner et al., 2014).
However, FcRn is known to be localized in EEA1-positive early
endosomes during uptake of IgG by kidney epithelial MDCK cells
(Jerdeva et al., 2010). This is in accordancewith the observation that
in human dermal microvascular EC (HMEC), FcRn and EEA1 were
co-localized in relatively large endosomes close to the nucleus
(Ward et al., 2005). Although EEA1 cannot be considered a perfect
surrogatemarker for the FcRn, the patterns of immunoﬂuorescence
staining of EEA1 in iBREC and of the FcRn in HMEC were strikingly
similar and at least a part of the taken up bevacizumab was seen in
EEA1-positive vesicles in the perinuclear region. This supports our
assumption, that bevacizumab associates with the FcRn duringuptake by iBREC and/or following transport processes. That not all
of the bevacizumab was co-localized with EEA1 may be due to
alternative pathways into and through the cells. This cannot be
ruled out but it seems more likely that only temporarily association
of antibody and FcRn is required for accurate processing. To study
transport or accumulation of a humanized MAb, we used retinal
endothelial cells of bovine origin, but for the following reasons we
believe that differences between species do not bring into question
the relevance of our results: Both bovine and human homologues
are highly conserved, the sequences of the IgG binding regions of
FcRn being identical (Kacskovics et al., 2000). Accordingly, binding
and releasing of human IgG by bovine FcRn in the process of efﬁ-
cient transcytosis has been demonstrated (Cui et al., 2014;
Kacskovics et al., 2006; Ober et al., 2001).
When the FcRn is not expressed, e.g. due to lack of stimulating
FBS (albumin) in the environment, or binding to the receptor is
blocked in an experimental setting, iBREC still can take up bev-
acizumab through another, then relevant pathway. Without the
option of accurate transcytosis or recycling, one would expect
degradation of the internalized IgG in lysosomes. Contradicting this
assumption, we observed after serum-free cultivation perinuclear
localization and accumulation of bevacizumab in the subcellular
fraction of cytoskeleton proteins which could be reversed by
addition of FBS, resulting in re-expression of the FcRn. In HMEC, a
complex formed by FcRn and IgG is shuttled from perinuclear
recycling endosomes to exosomes which then fuse with the plasma
membrane to subsequently release the IgG by exocytosis (Ward
Fig. 5. Temperature-dependent internalization and association with early endosomes
is indicative of an active uptake of bevacizumab by iBREC. (A) Bevacizumab was added
to conﬂuent iBREC which were then incubated for 4 h at 4 C or 37 C. More bev-
acizumab was taken up by iBREC kept at physiological 37 C when vesicle-mediated
transport prevails over passage through paracellular junctions. (B) iBREC were incu-
bated with bevacizumab for 4 h in mediumwithout or with 5% FBS. Bevacizumab (red),
the late endosome marker CD63 (green) or early endosome-speciﬁc EEA1 (green) were
visualized by immunoﬂuorescence staining. Overlapping staining for bevacizumab and
CD63 was not observed. Partial co-localization of bevacizumab and EEA1 was evident
particularly when iBREC had been incubated in medium containing 5% FBS. Variation
of the FBS concentration (0% or 5%) in the medium also resulted in different EEA1 and
CD63 staining patterns.
Fig. 6. Transport and localization of bevacizumab in iBREC is affected by Protein A (A)
Conﬂuent iBREC were exposed at the basal side (bottom chamber) to 2 mM (~250 mg/
ml) bevacizumab with or without an IgG-binding protein. Transendothelial transport
(þiBREC) of bevacizumab or its free diffusion (assay without cells, e iBREC) to the
upper chamber were assessed as described in Fig. 1A/B. Transport of bevacizumab was
strongly delayed by 5fold molar excess of Protein A (ﬁve IgG binding sites). (B)
Conﬂuent iBREC were treated as described in (A) for 4 h before subcellular protein
fractions were prepared and analyzed. When Protein A had been present in the culture
medium, bevacizumab was only detected in the fraction of cytoskeleton proteins. In
contrast, Protein L (four IgG binding sites) did not inﬂuence occurrence of bevacizumab
in the membrane/organelle fraction.
H.L. Deissler et al. / Experimental Eye Research 143 (2016) 49e59 57et al., 2005). Accordingly, sorting of bevacizumab to exosomes was
observed in experiments with porcine and human RPEC (Aboul
Naga et al., 2015). In iBREC, however, bevacizumab does not seem
to be sorted primarily to CD63-positive late secretory endosomes to
initiate its release from basal or apical sections of the membrane:
Even when exposure to bevacizumab had been extended to 24 h,
the internalized antibody was not found to be associated with
CD63-speciﬁc late endosomes and this was more pronounced in
the absence of FBS. We assume that this is cell type-speciﬁc
behavior of REC rather than a difference between species because
the sorting machinery involving the small Ras-like GTPases Rab11
(93% identical amino acids of human and bovine homologues) and
Rab4 (100% identity) is completely conserved (Ward et al., 2005).
Accumulation of bevacizumab which is then found in the cyto-
skeleton fractionmight be due to the high amount of foreign protein
the cells were exposed to, which simply overloaded the normal
intracellular processing system. Intracellular bevacizumab was
localized close to the intermediate ﬁlament vimentin and along a-
tubulin ﬁbers, particularly at their plus ends. These structures are
important for mechanic stability of the cells but also involved in
transport processes (reviewed in: Allan, 2009; Dave and Bayless,
2014). Interestingly, a similar dot-like bevacizumab staining asso-
ciated with actin ﬁlaments was seen after uptake of bevacizumab byporcine RPEC and human ARPE19 cells (Aboul Naga et al., 2015).
These observations invite the hypothesis that under normal physi-
ological conditions an internalized IgG like bevacizumab is trans-
ported along ﬁbers, resulting in its release or degradation. In the
presence of excessive amounts of IgG this process seems to be
substantially inhibited due to overloading which is even more
evident when the FcRn is weakly expressed in a low-serum envi-
ronment. Considering these effects, it is important to note that the
bevacizumab concentrations adjusted in our and other in-
vestigations can easily be achieved in vivo by intravitreal injection.
Transition of bevacizumab through an iBREC monolayer may be
promoted by VEGF-A165, the main therapeutic target of this anti-
body. VEGF-A165-induced permeability of a monolayer of (i)BREC is
due to enlarged caveolae and - at higher VEGF concentrations e the
disruption of TJ protein complexes from which plasma membrane
bound claudin-1 and occludin disappear (Deissler, 2008; Feng et al.,
1999; Harhaj, 2006). Although cellecell contacts remain stable
under these conditions, and (in contrast to EC of other tissues)
fenestration does not occur in the retinal endothelium in vivo,
paracellular ﬂow of macromolecules (>70 kDa) through mono-
layers of REC was observed (Feng et al., 1999; Harhaj et al., 2006;
Hofman et al., 2000). However, when both VEGF-A and bev-
acizumab are present in the environment, this effect of the growth
factor was widely neutralized, indicated by strong expression of the
TJ proteins claudin-1, claudin-5 and occludin and low permeability
of (i)BREC (Deissler et al., 2012, 2014). VEGF-induced paracellular
passage of a VEGF efﬁciently binding and inactivating antibody
seems therefore rather unlikely. This assumption was also sup-
ported by investigations showing that uptake of bevacizumab by
iBREC, cultivated with or without serum, was not accompanied by
reduction of the transendothelial resistance or the cell index
Fig. 7. Expression of FcRn by iBREC is affected by FBS. (A) Subcellular extracts were
prepared from iBREC exposed to 250 mg/ml bevacizumab in the presence of 5% FBS for
1 d. By Western blot analyses, the FcRn was only detected in membrane/organelle
fractions. (B) iBREC were cultivated in media containing different amounts of FBS for
24 h, then treated with 250 mg/ml bevacizumab for additional 2, 4 or 24 h before
subcellular fractions were prepared. iBREC strongly expressed the FcRn when culti-
vated in mediumwith serum, but only very weak FcRn-speciﬁc bands were seen when
membrane/organelle fractions of cells kept without serum for some time were
analyzed. (C) Conﬂuent iBREC were treated with 250 mg/ml bevacizumab for 2 d in
medium with 1% or 5% FBS, or in medium with 1% FBS for 1d before FBS was increased
to 5% for another day. Western blot analyses of membrane/organelle fractions showed
that the FcRn lost during cultivation of iBREC under low serum conditions could be
restored by increasing the amount of FBS.
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et al., 2012).
In the uptake of IgG by macrovascular EC, integrin complexes
are likely to play an important role, indicated by the capacity of
antibodies against the extracellular matrix protein ﬁbronectin or
integrins to inhibit this process (Fujii et al., 2003). Uptake and
transport of bevacizumab by the microvascular iBREC were only
slightly affected by ﬁbronectin and the IgG was not found co-
localized with CD29, the integrin subunit of the ﬁbronectin re-
ceptor. Based on this circumstantial evidence, however, an
involvement of integrin complexes cannot be ruled out
completely.
5. Conclusion
In summary, our results suggest the following pathway of bev-
acizumab uptake and transition through iBREC: Regardless of thepresence of FBS (or BSA), bevacizumab is taken up by iBREC through
a nonspeciﬁc mechanism to collect extracellular proteins. The
subsequent sorting into transport vesicles depends on the presence
of FBS or BSA as regulator of FcRn expression: The important role of
the FcRn, stored in acidic endosomes, was conﬁrmed by the ob-
servations that bevacizumab did no longer associate with proteins
of the membrane/organelle fraction when FcRn was absent or
binding to this receptor was blocked.Without sufﬁcient amounts of
the FcRn being expressed, e.g. as a consequence of low-serum
conditions, a likely obstructed exocytosis results in intracellular
accumulation and associationwith cytoskeleton proteins in regions
close to the nucleus. Interaction of substantial amount of bev-
acizumab with the cytoskeleton may be the reason for under these
conditions suppressed migration of otherwise unaffected iBREC
(Deissler et al., 2012). Whether strong accumulation of bev-
acizumab in REC occurs in vivo during long-term therapies of
ocular diseases, and potential harmful consequences remain to be
investigated.
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